Company Description
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific.
The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as well as treating acute stroke with tandem lesions.
It has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions.
The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Miami, Florida.
| Country | United States |
| Founded | 2005 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 86 |
| CEO | Marvin Slosman |
Contact Details
Address: 6303 Waterford District Drive, Suite 215 Miami, Florida 33126 United States | |
| Phone | 888 776 6804 |
| Website | inspiremd.com |
Stock Details
| Ticker Symbol | NSPR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001433607 |
| CUSIP Number | 45779A853 |
| ISIN Number | US45779A8466 |
| Employer ID | 26-2123838 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Marvin L. Slosman | President, Chief Executive Officer and Director |
| Craig Shore | Chief Financial Officer, Chief Administrative Officer, Secretary and Treasurer |
| Shane Thomas Gleason | Chief Commercial Officer |
| Andrea Tommasoli | Chief Operating Officer |
| Amir Kohen | Executive Vice President of Finance and Regional Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2025 | ARS | Filing |
| Apr 16, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 15, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2025 | EFFECT | Notice of Effectiveness |
| Apr 1, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 12, 2025 | 8-K | Current Report |
| Mar 12, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 7, 2025 | SCHEDULE 13G/A | Filing |
| Dec 12, 2024 | 8-K | Current Report |